Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.40
ACT's Cash-to-Debt is ranked lower than
75% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. ACT: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.4 Max: 25.09
Current: 0.4
0.02
25.09
Equity-to-Asset 0.59
ACT's Equity-to-Asset is ranked lower than
54% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. ACT: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.58 Max: 0.75
Current: 0.59
0.27
0.75
Piotroski F-Score: 6
Altman Z-Score: 1.27
Beneish M-Score: -1.86
WACC vs ROIC
7.95%
-0.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -12.08
ACT's Operating Margin % is ranked lower than
79% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. ACT: -12.08 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -12.08
-54.9
14.13
Net Margin % 100.04
ACT's Net Margin % is ranked higher than
99% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACT: 100.04 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.67 Max: 102.76
Current: 100.04
-34.87
102.76
ROE % 18.53
ACT's ROE % is ranked higher than
81% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ACT: 18.53 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 18.53
-11.23
19.24
ROA % 11.06
ACT's ROA % is ranked higher than
81% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACT: 11.06 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 11.32
Current: 11.06
-4.32
11.32
ROC (Joel Greenblatt) % -58.53
ACT's ROC (Joel Greenblatt) % is ranked lower than
81% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. ACT: -58.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -117.72  Med: 20.42 Max: 38.44
Current: -58.53
-117.72
38.44
3-Year Revenue Growth Rate 27.40
ACT's 3-Year Revenue Growth Rate is ranked higher than
90% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ACT: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 16.2 Max: 27.4
Current: 27.4
-16.3
27.4
3-Year EBITDA Growth Rate 41.70
ACT's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. ACT: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 3.6 Max: 41.7
Current: 41.7
-47.7
41.7
3-Year EPS without NRI Growth Rate -1.20
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ACT: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: -0.1 Max: 19.7
Current: -1.2
-27.1
19.7
GuruFocus has detected 2 Warning Signs with Allergan PLC $ACT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACT's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA839.696.555 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:ESALF, OTCPK:SGIOY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:APNHY, NYSE:PRGO, OTCPK:HLUKF, OTCPK:SFOSF, OTCPK:IPSEY, OTCPK:GNHAF, NYSE:RDY, OTCPK:HYPMY, NYSE:TARO, NYSE:MNK, NAS:OPK, NYSE:PTHN » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan is one of the largest specialty pharmaceutical manufacturers. Allergan specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 6.19
ACT's PE Ratio is ranked higher than
95% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.26 vs. ACT: 6.19 )
Ranked among companies with meaningful PE Ratio only.
ACT' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 24.72 Max: 366.63
Current: 6.19
4.95
366.63
Forward PE Ratio 14.84
ACT's Forward PE Ratio is ranked higher than
61% of the 109 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. ACT: 14.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.78
ACT's Price-to-Owner-Earnings is ranked higher than
94% of the 302 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. ACT: 4.78 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.82  Med: 18.5 Max: 1421.16
Current: 4.78
3.82
1421.16
PB Ratio 1.25
ACT's PB Ratio is ranked higher than
83% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ACT: 1.25 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.25
0.87
5.9
PS Ratio 6.21
ACT's PS Ratio is ranked lower than
74% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ACT: 6.21 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 6.21
0.99
17.57
Price-to-Free-Cash-Flow 86.87
ACT's Price-to-Free-Cash-Flow is ranked lower than
84% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. ACT: 86.87 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 15.38 Max: 90.54
Current: 86.87
6.62
90.54
Price-to-Operating-Cash-Flow 66.24
ACT's Price-to-Operating-Cash-Flow is ranked lower than
87% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. ACT: 66.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.97  Med: 12.67 Max: 69.03
Current: 66.24
5.97
69.03
EV-to-EBITDA 20.35
ACT's EV-to-EBITDA is ranked lower than
64% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. ACT: 20.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 11.9 Max: 589.4
Current: 20.35
-224.1
589.4
Shiller PE Ratio 51.83
ACT's Shiller PE Ratio is ranked lower than
56% of the 164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.73 vs. ACT: 51.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96  Med: 53.8 Max: 2307.73
Current: 51.83
18.96
2307.73
Current Ratio 2.27
ACT's Current Ratio is ranked lower than
52% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. ACT: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.45 Max: 5.51
Current: 2.27
1.03
5.51
Quick Ratio 2.18
ACT's Quick Ratio is ranked higher than
58% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. ACT: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.77 Max: 4.38
Current: 2.18
0.8
4.38
Days Inventory 130.69
ACT's Days Inventory is ranked lower than
57% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. ACT: 130.69 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 108.11  Med: 126.6 Max: 369.82
Current: 130.69
108.11
369.82
Days Sales Outstanding 61.72
ACT's Days Sales Outstanding is ranked higher than
63% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. ACT: 61.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 61.72
39.05
197.04
Days Payable 37.39
ACT's Days Payable is ranked lower than
81% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. ACT: 37.39 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 69.22 Max: 109.48
Current: 37.39
28.64
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.10
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. ACT: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6 Max: 2
Current: -29.1
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.22
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. ACT: 1.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.19 Max: 2.96
Current: 1.22
0.6
2.96
Price-to-Median-PS-Value 3.38
ACT's Price-to-Median-PS-Value is ranked lower than
92% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. ACT: 3.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.47 Max: 5.54
Current: 3.38
0.67
5.54
Earnings Yield (Greenblatt) % -1.46
ACT's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. ACT: -1.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.46  Med: 6.1 Max: 12.3
Current: -1.46
-1.46
12.3
Forward Rate of Return (Yacktman) % 5.21
ACT's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.75 vs. ACT: 5.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 7.2 Max: 16.1
Current: 5.21
-8.7
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
The Most Attractive Value Stock There Is? Mar 23 2017 
Corporate Share Repurchases Decline for 2nd Year in a Row Mar 22 2017 
David Tepper Takes Big Risks for Big Rewards Mar 21 2017 
Scott Black Continues to Buy Allergan, CVS Health, 6 Others Mar 16 2017 
David Tepper Discusses Allergan Investment, Market Valuation Mar 08 2017 
Jeff Auxier Invests in Gilead, Wells Fargo, Apple Mar 06 2017 
Jerome Dodson Adds to 9 Positions in 4th Quarter Mar 01 2017 
Big Money Still Long Valeant Feb 28 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Where Seth Klarman Sees Value in Today’s Market Feb 15 2017 

More From Other Websites
Are Hedge Funds Turning Bearish on Healthcare Stocks? Mar 08 2017
Supernus Pharma Tanks on Settlement of Two Patent Disputes (SUPN) Mar 08 2017
The Best Dividend Investors Are Preparing For Higher Interest Rates Mar 02 2017
Jerome Dodson Adds to 9 Positions in 4th Quarter Mar 01 2017
The Zacks Analyst Blog Highlights: IBM, Allergan, Chubb, DISH Network and HP Feb 27 2017
Facing Criticism, Drug Makers Keep Lid On Price Increases Feb 27 2017
Drug Companies Keep Lid on Price Increases Feb 26 2017
Insider Q&A: Allergan CEO on impact of limiting price hikes Feb 26 2017
Insider Q&A: Allergan CEO on impact of limiting price hikes Feb 26 2017
Top Research Reports for February 24, 2017 Feb 24 2017
Allergan CEO Pushes for Trump to Lead Drug Price Discussions Feb 22 2017
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
5 Ways Allergan Can Keep Up Momentum Feb 15 2017
Billionaire Dan Loeb’s Biggest Q4 Moves Include Bank-Buying Spree, Selling Allergan (AGN) Feb 15 2017
David Tepper's Appaloosa just dropped about $1 billion on 4 pharma stocks Feb 14 2017
Appaloosa Management snaps up Allergan shares in 4th quarter Feb 14 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit Feb 14 2017
Botox-maker Allergan is betting that zapping your fat is worth $4 billion Feb 14 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to spend $2.48 B on CoolSculpting provider Zeltiq Feb 13 2017
Allergan reports 4Q loss Feb 08 2017
Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European... Jan 09 2017
Allergan to buy Acelity's tissue unit LifeCell for $2.9 bln Dec 20 2016
Allergan to buy Acelity's tissue unit LifeCell for $2.9 bln Dec 20 2016
Acelity to Sell LifeCell Business Unit to Allergan Dec 20 2016
Actavis UK accused of overcharging hydrocortisone drug Dec 16 2016
Actavis UK raised drug prices 12,000 percent, watchdog finds Dec 16 2016
Actavis UK raised drug prices 12,000 pct, watchdog finds Dec 16 2016
Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin... Oct 31 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
AstraZeneca licenses inflammatory disease candidate to Allergan Oct 03 2016
US STOCKS-Wall St ends flat with Fed, BOJ up next Sep 20 2016
US STOCKS-Wall St buoyed by healthcare with Fed on deck Sep 20 2016
Allergan vows limited price hikes, says 'outliers' deter research Sep 06 2016
Allergan reports 2Q loss Aug 08 2016
US STOCKS-Wall Street takes tiny step back from record highs Aug 08 2016
US STOCKS-Wall Street steps back from record highs Aug 08 2016
Business groups sue over new U.S. limit on tax-driven foreign buyouts Aug 05 2016
Business groups sue over new U.S. limit on tax-driven foreign buyouts Aug 05 2016
Business groups sue over new U.S. limit on tax-driven foreign buyouts Aug 04 2016
Biogen not pursuing a sale - source Aug 03 2016
Biogen not pursuing a sale - source Aug 03 2016
Allergan to sell Anda drug distribution business to Teva Aug 03 2016
Biogen draws takeover interest from Merck, Allergan - WSJ Aug 02 2016
Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Mayne Pharma buys Teva drugs for $US652m Jun 28 2016
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR® May 10 2016
Allergan said to be exploring split into two businesses - source Jul 24 2015
Allergan said to be exploring split into two businesses - Bloomberg Jul 24 2015
Eli Lilly wins UK Alimta drug patent case on appeal, shares jump Jun 25 2015
Carl Icahn says underweight Apple bets will hurt funds' performance May 21 2015
Actavis says Warner Chilcott unit held talks to settle U.S. probe May 14 2015
US stocks fall as market eyes Greece talks May 11 2015
US STOCKS-Wall St mixed at open; energy shares fall May 11 2015
US STOCKS-Futures little changed after soaring last week on strong jobs data May 11 2015
US STOCKS-Futures slightly down after soaring last week on strong jobs data May 11 2015
Teva Pharmaceutical offers to buy Mylan for $40.1 bn Apr 21 2015
Generic drugmaker Mylan offers $29 bln for Perrigo Apr 08 2015
US bond market buckles after surge Mar 23 2015
Eli Lilly loses Alimta drug patent case in Germany to Actavis Mar 06 2015
TREASURIES-Bond prices slip on corporate supply; U.S. data eyed Mar 03 2015
TREASURIES-Bond prices flat on corporate supply, U.S. debt demand Mar 03 2015
AstraZeneca's patent on asthma drug invalidated by U.S. court Feb 15 2015
Actavis mulls job cuts, China expansion - Bloomberg Nov 24 2014
Exclusive - Actavis plans new merger approach for Allergan - sources Oct 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)